CN Patent

CN104356092B — 沃替西汀的制备方法

Assigned to HEFEI CHUANGXIN MEDICAL TECHNOLOGY Co Ltd · Expires 2017-03-22 · 9y expired

What this patent protects

本发明涉及药物合成领域，具体而言涉及一种抗抑郁药物中间体沃替西汀的制备新方法，包括2,4‑二甲基苯硫酚与2‑卤素氯苯反应得到中间体2‑（2,4‑二甲基苯基硫基）氯苯，该中间体再与哌嗪反应得到沃替西汀。本发明中沃替西汀的总收率能够达到68%～75%,该工艺具有起始原料廉价易得，工艺简洁的优点，符合大生产要求。

USPTO Abstract

本发明涉及药物合成领域，具体而言涉及一种抗抑郁药物中间体沃替西汀的制备新方法，包括2,4‑二甲基苯硫酚与2‑卤素氯苯反应得到中间体2‑（2,4‑二甲基苯基硫基）氯苯，该中间体再与哌嗪反应得到沃替西汀。本发明中沃替西汀的总收率能够达到68%～75%,该工艺具有起始原料廉价易得，工艺简洁的优点，符合大生产要求。

Drugs covered by this patent

vortioxetine-hydrobromide (VORTIOXETINE HYDROBROMIDE)

Patent Metadata

Patent number: CN104356092B
Jurisdiction: CN
Classification: —
Expires: 2017-03-22
Drug substance claim: No
Drug product claim: No
Assignee: HEFEI CHUANGXIN MEDICAL TECHNOLOGY Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.